Abstract: SA-OR011

Impact on Blood Pressure of Mobile-Based Application (eKidneyCare) in Patients with CKD: A Randomized Controlled Trial

Session Information

Category: Chronic Kidney Disease (Non-Dialysis)

  • 307 CKD: Health Services, Disparities, Prevention


  • Ong, Stephanie W., University Health Network, Toronto, Ontario, Canada
  • Jassal, Sarbjit Vanita, University Health Network, Toronto, Ontario, Canada
  • Min, Kelly, University Health Network, Toronto, Ontario, Canada
  • Uddin, Akib, University Health Network, Toronto, Ontario, Canada
  • Porter, Eveline C, University Health Network, Toronto, Ontario, Canada
  • Tomlinson, George, University Health Network, Toronto, Ontario, Canada
  • Logan, Alexander G., Mount Sinai Hospital, Toronto, Ontario, Canada

We have previously demonstrated feasibility and acceptability of an integrated app (eKidneyCare) used for CKD management (CJASN 2016). It allows patients to monitor blood pressure (BP), manage medication, assess symptoms and track laboratory results. Customizable algorithms provide real-time personalized patient feedback and alerts to providers. Currently we are performing a one-year randomized controlled trial comparing eKidneyCare (intervention) to MyMedRec (control). The latter is a commercially available app that records medical information without providing feedback. Study midpoint results are presented.


Consenting patients with CKD 3b-5 or 5D were recruited from 6 out-patient renal clinics or dialysis units at University Health Network (UHN) and randomized to eKidneyCare or MyMedRec monitoring. Outcome assessments include BP at 6 and 12 months and medication reconciliation, questionnaires on self-management and, at study end, in-person interviews.


A total of 182 patients were enrolled and randomly allocated to the intervention (n=89) or the control (n=93) group. A total of 157 patients completed the 6 month BP assessment using the automated oscillometric device, BpTRU. Premature withdrawals included 11 transferred or incomplete data, 8 who withdrew consent and 6 withdrawn after medical complications. At 6m, the fall in BP of patients with uncontrolled hypertension at baseline was greater in the active (eKidneyCare) group (median reduction in systolic BP mmHg -18 vs 13 mmHg respectively, p =0.05; diastolic BP 9 vs 5.5 mmHg p=0.03). There was no between group difference in normotensive patients.


Hypertensive patients allocated to the eKidneyCare app had a significantly lower BP than those using the commercially available app. This preliminary analysis suggests that real time patient feedback and integrated mobile apps are critical components for success with mHealth monitoring.


  • Other NIH Support